Galectin Common Stock Shares Outstanding from 2010 to 2024
| GALT Stock | USD 3.50 0.01 0.28% |
Common Stock Shares Outstanding | First Reported 2001-03-31 | Previous Quarter 59.7 M | Current Value 61.9 M | Quarterly Volatility 20.8 M |
Check Galectin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galectin main balance sheet or income statement drivers, such as Depreciation And Amortization of 44.8 K, Selling General Administrative of 5.6 K or Other Operating Expenses of 40 M, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0021 or Days Sales Outstanding of 0.0. Galectin financial statements analysis is a perfect complement when working with Galectin Therapeutics Valuation or Volatility modules.
Galectin | Common Stock Shares Outstanding |
Latest Galectin Therapeutics' Common Stock Shares Outstanding Growth Pattern
Below is the plot of the Common Stock Shares Outstanding of Galectin Therapeutics over the last few years. It is the total number of shares of a company's common stock that are currently owned by all its shareholders. Galectin Therapeutics' Common Stock Shares Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galectin Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Shares Outstanding | 10 Years Trend |
|
Common Stock Shares Outstanding |
| Timeline |
Galectin Common Stock Shares Outstanding Regression Statistics
| Arithmetic Mean | 36,445,463 | |
| Geometric Mean | 28,089,423 | |
| Coefficient Of Variation | 56.84 | |
| Mean Deviation | 17,974,228 | |
| Median | 35,521,000 | |
| Standard Deviation | 20,716,501 | |
| Sample Variance | 429.2T | |
| Range | 61.1M | |
| R-Value | 0.98 | |
| Mean Square Error | 14.4T | |
| R-Squared | 0.97 | |
| Slope | 4,559,545 | |
| Total Sum of Squares | 6008.4T |
Galectin Common Stock Shares Outstanding History
About Galectin Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Galectin Therapeutics income statement, its balance sheet, and the statement of cash flows. Galectin Therapeutics investors use historical funamental indicators, such as Galectin Therapeutics's Common Stock Shares Outstanding, to determine how well the company is positioned to perform in the future. Although Galectin Therapeutics investors may use each financial statement separately, they are all related. The changes in Galectin Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Galectin Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Galectin Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Galectin Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 60.2 M | 63.2 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Galectin Therapeutics Correlation against competitors. For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Galectin Stock analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Galectin Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galectin Therapeutics. If investors know Galectin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galectin Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Return On Assets (0.96) | Return On Equity (37.28) |
The market value of Galectin Therapeutics is measured differently than its book value, which is the value of Galectin that is recorded on the company's balance sheet. Investors also form their own opinion of Galectin Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Galectin Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galectin Therapeutics' market value can be influenced by many factors that don't directly affect Galectin Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galectin Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galectin Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galectin Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.